Cargando…

Real‐world study of next‐generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan

Our previous real‐world studies raised concerns that sequential biomarker testing may lead to increased time to treatment when compared with simultaneous single biomarker testing. The Oncomine Dx target test (ODxTT), a next‐generation sequencing–based multiplex biomarker panel test approved in Japan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Toshiaki, Nishio, Makoto, Nishino, Kazumi, Yoshiki, Yasumasa, Shiraiwa, Naoko, Emir, Birol, Iadeluca, Laura, Yatabe, Yasushi, Nishio, Kazuto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236614/ https://www.ncbi.nlm.nih.gov/pubmed/36751989 http://dx.doi.org/10.1111/cas.15752

Ejemplares similares

Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan
por: Yatabe, Yasushi, et al.
Publicado: (2020)

New Era for Next-Generation Sequencing in Japan
por: Takeda, Masayuki, et al.
Publicado: (2019)

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study
por: Waterhouse, David, et al.
Publicado: (2021)

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Real‐world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2023)

An effective screening strategy for deafness in combination with a next-generation sequencing platform: a consecutive analysis
por: Sakuma, Naoko, et al.
Publicado: (2016)

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing
por: Iwama, Eiji, et al.
Publicado: (2018)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
por: Suda, Kenichi, et al.
Publicado: (2015)

Lung cancer biomarker tests: the history and perspective in Japan
por: Motoi, Noriko, et al.
Publicado: (2020)

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

Psychotropic drug use rate among detention house residents and association with the category of the crimes in Japan
por: Nishio, Akihiro
Publicado: (2021)

Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance
por: Inagaki, Nobuya, et al.
Publicado: (2021)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

The Clinical Next‐Generation Sequencing Database: A Tool for the Unified Management of Clinical Information and Genetic Variants to Accelerate Variant Pathogenicity Classification
por: Nishio, Shin‐ya, et al.
Publicado: (2017)

Strategies to Address Current Challenges in Real-World Evidence Generation in Japan
por: Laurent, Thomas, et al.
Publicado: (2023)

Impact of chronic urticaria on quality of life and work in Japan: Results of a real‐world study
por: Itakura, Asako, et al.
Publicado: (2018)

Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)
por: Shimizu, Junichi, et al.
Publicado: (2020)

Educational outcomes of a medical physicist program over the past 10 years in Japan
por: Kadoya, Noriyuki, et al.
Publicado: (2017)

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
por: Nishio, Kazuto, et al.
Publicado: (2023)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ariyasu, Ryo, et al.
Publicado: (2023)

HEP experiments in Japan: The Next Generation
por: Itoh, Ryosuke
Publicado: (2009)

Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study
por: Okamoto, Isamu, et al.
Publicado: (2014)

Knowledge of Chronic Kidney Disease among the General Population: A Questionnaire Survey in Hokkaido Prefecture, Japan
por: Nakagawa, Naoki, et al.
Publicado: (2022)

Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan
por: Hiramatsu, Katsutoshi, et al.
Publicado: (2021)

Lingering effects of COVID-19 on the mental health of first-year university students in Japan
por: Horita, Ryo, et al.
Publicado: (2022)

Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
por: Ariyasu, Ryo, et al.
Publicado: (2020)

Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data
por: Suh, Koung Jin, et al.
Publicado: (2022)

Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA
por: Sunami, Kuniko, et al.
Publicado: (2021)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
por: Ohtani, Seiya, et al.
Publicado: (2023)

Healthcare Costs of Smokers Using Varenicline Versus Nicotine-Replacement Therapy Patch in the United States: Evidence from Real-World Practice
por: Lee, Lauren J., et al.
Publicado: (2018)

Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
por: Ando, Yukio, et al.
Publicado: (2023)

Quantifying The Burden of Persistent Musculoskeletal Pain in Employees at Rolls-Royce in The United Kingdom: A Real-World Cross-Sectional Survey
por: Abraham, Lucy, et al.
Publicado: (2023)

Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
por: Fukumoto, Hisao, et al.
Publicado: (1997)

Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan
por: Takazono, Takahiro, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database
por: Tacke, Frank, et al.
Publicado: (2022)

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
por: Nishio, Makoto, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kgj4d584uhch49dovgmsq4226m